Summit Therapeutics Inc. (SMMT) earnings date

Nasdaq · Large cap · EDGAR filings

Email me when this date changes · free account, one click to stop

How this company behaves

Announces its report date Not enough announcements on file yet to say
Reports after the quarter ends 33 days, typically, give or take 13 (last 8 releases)

Last 8 releases

PeriodReleasedTimingDays after period endFiling
Q3 FY2026Wed, Nov 4, 2026after close 35 8-K
Q2 FY2026Thu, Jul 23, 2026after close 23 8-K
Q1 FY2026Thu, Apr 30, 2026after close 30 8-K
Q4 FY2025Mon, Feb 23, 2026after close 54 8-K
Q3 FY2025Mon, Oct 20, 2025before open 20 8-K
Q2 FY2025Mon, Aug 11, 2025after close 42 8-K
Q1 FY2025Thu, May 1, 2025after close 31 8-K
Q4 FY2024Mon, Feb 24, 2025before open 55 8-K

What they guided beta

Q3 FY2026 "The number of PFS events needed in the squamous cohort for the primary analysis is expected to be reached in the fourth quarter of 2026, and a planned early interim analysis for OS is expected to take place in conjunction with the primary PFS analysis." exhibit
Q3 FY2026 "For the non-squamous cohort, the number of events needed to conduct the PFS analysis is expected to be reached in the first half of 2027." exhibit
Q3 FY2026 "Summit's global Phase III HARMONi-7 trial continues to enroll, with enrollment expected to be completed in 2027." exhibit
Q3 FY2026 "The enrollment rate has exceeded initial estimations and is currently expected to complete in Q3 2027." exhibit
Q3 FY2026 "In September 2026, Summit entered into a clinical trial collaboration with AstraZeneca to evaluate ivonescimab in combination with AstraZeneca’s Claudin 18.2-targeting ADC, sonesitatug vedotin, also referred to as sone- ve, in certain gastrointestinal cancer settings." exhibit
Q2 FY2026 "HARMONi-3 Global Phase III 1L NSCLC Study: Squamous Cohort Final PFS Analysis Events Expected to Be Reached in Second Half of 2026 with Interim OS Analyses Planned; Non-Squamous Cohort PFS Events Expected to Be Reached in the First Half of 2027" exhibit
Q2 FY2026 "The number of PFS events needed in the squamous cohort for the primary analysis is expected to be reached in the second half of 2026, and a planned early interim analysis for OS is expected to take place" exhibit
Q2 FY2026 "For the non-squamous cohort, the number of events needed to conduct the PFS analysis is expected to be reached in the first half of 2027." exhibit
Q2 FY2026 "Data from the study under this collaboration agreement is expected to be generated by mid-2027." exhibit
Q2 FY2026 "During the second quarter of 2026, the company raised $230.8 million in gross proceeds through its ATM facility." exhibit

Get this as JSON

curl -H "X-API-Key: vt_live_..." https://api.veritasdata.dev/v1/next/SMMT
# how far back the record goes for this company
curl -H "X-API-Key: vt_live_..." https://api.veritasdata.dev/v1/coverage/SMMT

Put this date on your page

A badge that stays current. It links back to this page and needs no key. Embed it unmodified, with its link to this page intact: the badge is too small to carry the notice below, so the page it links to does.

Read by software from public filings and company announcements. Can be wrong. Verify with the company or the SEC. Not investment advice.

SMMT earnings date badge

HTML

<a href="https://veritasdata.dev/company/SMMT/"><img src="https://veritasdata.dev/embed/SMMT.svg" alt="SMMT earnings date" width="240" height="56"></a>

Markdown

[![SMMT earnings date](https://veritasdata.dev/embed/SMMT.svg)](https://veritasdata.dev/company/SMMT/)

Script

<script async src="https://veritasdata.dev/embed/SMMT.js"></script>

Get a free key: 100 calls, every company

Sign in with GitHub or Google. The key works on every endpoint and in the MCP server.

curl -H "X-API-Key: vt_live_..." "https://api.veritasdata.dev/v1/next/SMMT"

Dates come only from SEC EDGAR and company announcements. Nothing here is investment advice.